论文部分内容阅读
目的比较安搏诺(厄贝沙坦/氢氯噻嗪)与安搏维(厄贝沙坦)对中老年高血压的治疗效果。方法将64例经基础降压治疗后仍未达标(达标标准<150/90mmHg)的中老年高血压患者随机分为2组,一组加用安搏诺(厄贝沙坦150mg/氢氯噻嗪12.5mg),另一组加用安搏维(厄贝沙坦150mg),两药均每日1次,口服治疗12周,观察血压、心率、血尿酸,血肌酐、血钾、血糖的变化。结果降压总有效率:安搏诺组为87.5%,安搏维组为81.5%;达标率安搏诺组为90.6%,安搏维组为83.3%;两组在治疗12周后相比血压,心率及血钾、血肌酐、血尿酸、血糖等指标较治疗前无明显差异;两药不良反应轻微,未发现明显的不良反应。结论安搏诺与安搏维治疗中老年高血压在疗效、安全性和药物的依从性方面均较好,相比之下安搏诺起效更快,降压有效率、达标率更高。
Objective To compare the therapeutic effects of diazepam (irbesartan / hydrochlorothiazide) and ambroxol (irbesartan) on middle-aged and elderly patients with hypertension. Methods Sixty-four middle-aged and elderly patients with hypertension who did not reach the standard (standard <150 / 90mmHg) after basic antihypertensive treatment were randomly divided into two groups. One group was given risperidone (irbesartan 150mg / hydrochlorothiazide 12.5mg ), And another group with Anbo Wei (irbesartan 150 mg). Both drugs were given once daily for 12 weeks. The changes of blood pressure, heart rate, serum uric acid, serum creatinine, serum potassium and blood glucose were observed. Results The total effective rate of antihypertensive group was 87.5% in AnPuOuo group and 81.5% in AnboWu group, 90.6% in AUPO group and 83.3% in AnboWu group, respectively Blood pressure, heart rate and serum potassium, serum creatinine, serum uric acid, blood glucose and other indicators no significant difference before treatment; two adverse reactions were minor, no significant adverse reactions. CONCLUSIONS: Allopurinol and Anephoxol are effective in treating middle-aged and elderly patients with hypertension in their efficacy, safety and drug compliance. In contrast, risperidone has faster onset, effective antihypertensive efficacy and higher compliance rate.